Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts

British Journal of Cancer

Volumn 111, Issue 6, 2014, Pages 1159-1167

  Chiu, M ^a   Tardito, S ^a,e   Pillozzi, S ^b   Arcangeli, A ^b   Armento, A ^a   Uggeri, J ^a   Missale, G ^c   Bianchi, M G ^a   Barilli, A ^a   Dall'Asta, V ^a   Campanini, N ^a   Silini, E M ^a   Fuchs, J ^d   Armeanu Ebinger, S ^d   Bussolati, O ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

asparaginase; glutamine; Glutamine synthetase; hepatocellular carcinoma; liver cancer; methionine L sulfoximine; catenin

Indexed keywords

ASPARAGINASE; BETA CATENIN; CATENIN BETA 1; GLUTAMATE AMMONIA LIGASE; MAMMALIAN TARGET OF RAPAMYCIN; METHIONINE SULFOXIMINE; S6 KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ASPARAGINE; CADHERIN; CTNNB1 PROTEIN, HUMAN; ENZYME INHIBITOR; GLUTAMINE; KI 67 ANTIGEN;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HEPG2 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MALE; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR WEIGHT; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENETICS; LIVER TUMOR; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARAGINE; BETA CATENIN; CADHERINS; CARCINOMA, HEPATOCELLULAR; ENZYME INHIBITORS; GLUTAMATE-AMMONIA LIGASE; GLUTAMINE; HEP G2 CELLS; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; METHIONINE SULFOXIMINE; MICE; MICE, NUDE; MUTATION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908360969     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.425     Document Type: Article

References (37)

1. Armeanu-Ebinger S, Wenz J, Seitz G, Leuschner I, Handgretinger R, Mau-Holzmann UA, Bonin M, Sipos B, Fuchs J, Warmann SW (2012) Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma. PLoS One 7: e38223.
2. Aslanian AM, Kilberg MS (2001) Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J 358: 59-67.
3. Avramis VI (2012) Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res 32: 2423-2437.
4. Behari J, Zeng G, Otruba W, Thompson MD, Muller P, Micsenyi A, Sekhon SS, Leoni L, Monga SP (2007) R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol 46: 849-857.
5. Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, Idle JR (2013) Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 58: 229-238.
6. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52.
7. Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A (2006) Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res 8: R31.
8. Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25: 169-193.
9. Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers WH, Kitajewski J, Kahn A, Perret C (2002) New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21: 8293-8301.
10. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, DeBerardinis RJ (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA 108: 8674-8679.
11. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Sole M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68: 6779-6788.
12. Chiu M, Tardito S, Barilli A, Bianchi MG, DallAsta V, Bussolati O (2012) Glutamine stimulates mTORC1 independent of the cell content of essential amino acids. Amino Acids 43: 2561-2567.
13. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP (2009) Unique phenotype of hepatocellular cancers with exon-3 mutations in betacatenin gene. Hepatology 49: 821-831.
14. Covini D, Tardito S, Bussolati O, Chiarelli LR, Pasquetto MV, Digilio R, Valentini G, Scotti C (2012) Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat Anticancer Drug Discov 7: 4-13.
15. Dal Bello B, Rosa L, Campanini N, Tinelli C, Torello Viera F, DAmbrosio G, Rossi S, Silini EM (2010) Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res 16: 2157-2166.
16. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104: 19345-19350.
17. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118-1127.
18. Emre S, McKenna GJ (2004) Liver tumors in children. Pediatr Transplant 8: 632-638.
19. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
20. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
21. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, Zucman-Rossi J (1999) Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 18: 4044-4046.
22. Nejak-Bowen KN, Monga SP (2011) Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 21: 44-58.
23. Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B (1988) Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 18: 512-516.
24. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS, Wang XW (2012) Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 142: 957-966 e912.
25. Rotoli BM, Uggeri J, DallAsta V, Visigalli R, Barilli A, Gatti R, Orlandini G, Gazzola GC, Bussolati O (2005) Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem 15: 281-292.
26. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD (2009) Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 3: 353-367.
27. Singh B, Tai K, Madan S, Raythatha MR, Cady AM, Braunlin M, Irving LR, Bajaj A, Lucci A (2012) Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One 7: e36510.
28. Tardito S, Chiu M, Franchi-Gazzola R, DallAsta V, Comi P, Bussolati O (2012) The non-proteinogenic amino acids L-methionine sulfoximine and DL-phosphinothricin activate mTOR. Amino Acids 42: 2507-2512.
29. Tardito S, Chiu M, Uggeri J, Zerbini A, Da Ros F, DallAsta V, Missale G, Bussolati O (2011) L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets 11: 929-943.
30. Tardito S, Uggeri J, Bozzetti C, Bianchi MG, Rotoli BM, Franchi-Gazzola R, Gazzola GC, Gatti R, Bussolati O (2007) The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol 60: 751-758.
31. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H, Mikulits W (2009) Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5: 1169-1179.
32. White BD, Chien AJ, Dawson DW (2012) Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology 142: 219-232.
33. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-18787.
34. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
35. Zeng G, Apte U, Cieply B, Singh S, Monga SP (2007) siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 9: 951-959.
36. Zhang B, Dong LW, Tan YX, Zhang J, Pan YF, Yang C, Li MH, Ding ZW, Liu LJ, Jiang TY, Yang JH, Wang HY (2013) Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer 109: 14-23.
37. Zhao Y, Butler EB, Tan M (2013) Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4: e532.